A woman taking suvorexant (Belsomra) 15 mg at night reports only about five hours of sleep, early awakening, racing thoughts during sleep, and facial fatigue in the morning; what management steps should be taken?

Inadequate Response to Suvorexant 15 mg: Management Recommendations

Switch to cognitive behavioral therapy for insomnia (CBT-I) as the primary intervention, as this patient is experiencing inadequate response to suvorexant with only 5 hours of sleep, early awakening, racing thoughts, and morning facial fatigue—symptoms suggesting the medication is not effectively addressing her insomnia disorder. 1

Why This Patient Needs a Different Approach

This woman's symptoms indicate treatment failure on suvorexant 15 mg:

• Only 5 hours of sleep (insufficient total sleep time)
• Early morning awakening (sleep maintenance failure)
• Racing thoughts during sleep (suggests inadequate suppression of wake-promoting systems)
• Facial fatigue/tiredness (daytime dysfunction persisting)

The FDA label explicitly states: "Call your doctor if your insomnia (sleep problem) worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problem." 2

Evidence-Based Management Algorithm

Step 1: Transition to CBT-I (First-Line Treatment)

CBT-I should be the initial treatment for chronic insomnia disorder per American College of Physicians guidelines (strong recommendation, moderate-quality evidence). 1 This includes:

• Sleep restriction therapy to consolidate sleep
• Stimulus control to reassociate bed with sleep
• Cognitive therapy to address racing thoughts specifically
• Sleep hygiene education

The racing thoughts she experiences are particularly amenable to the cognitive component of CBT-I, which directly targets hyperarousal and intrusive cognitions.

Step 2: Consider Dose Adjustment Only If CBT-I Cannot Be Accessed Immediately

If CBT-I is not immediately available, you could consider increasing to suvorexant 20 mg (the maximum approved dose). However, this is a weaker option because:

• Evidence shows suvorexant 20/15 mg (non-elderly/elderly dosing) has modest effects, with the 15 mg dose showing "less evident" onset effects at later time points 3
• The FDA warns that the 20 mg dose carries higher risk of next-day impairment and driving problems 2
• Her current symptoms suggest the mechanism (orexin antagonism) may not be adequately addressing her specific insomnia phenotype

Step 3: Evaluate for Contributing Factors

Before any medication adjustment, assess:

• Timing of administration: Is she taking it within 30 minutes of bed and staying in bed for at least 7 hours? 2
• Food intake: Taking with meals delays absorption and reduces efficacy 4
• Alcohol use: Contraindicated with suvorexant 2
• Concurrent medications: CYP3A inhibitors increase suvorexant levels 4
• Underlying conditions: Depression, anxiety, sleep apnea, or other medical conditions that may be primary drivers

The racing thoughts particularly raise concern for an anxiety or mood disorder that requires separate treatment.

Critical Safety Considerations

The FDA label warns about cognitive and behavioral changes with suvorexant, including:

• Abnormal dreams (which may relate to her "racing thoughts during sleep") 2
• Worsening depression and suicidal thoughts 2
• Sleep paralysis and temporary leg weakness 2

If she reports worsening mood or suicidal ideation, discontinue suvorexant immediately and evaluate for psychiatric comorbidity. 2

Why Not Simply Increase the Dose?

While suvorexant can be increased to 20 mg, the evidence shows:

• Comparative effectiveness data for insomnia pharmacotherapies is insufficient or low strength 5
• Observational studies link hypnotics to increased risk of dementia, fractures, and major injury 5
• The long-term efficacy of pharmacotherapies for insomnia is not known 5
• Her symptoms suggest inadequate response rather than inadequate dosing

Practical Implementation

Immediate actions:

1. Refer to CBT-I (in-person, telephone, or web-based modules are all effective) 1
2. Screen for depression/anxiety given racing thoughts
3. Review medication timing, food intake, and alcohol use
4. Consider sleep diary for 1-2 weeks to objectively assess sleep patterns

If CBT-I fails or is unavailable:

• Use shared decision-making to discuss risks/benefits of increasing to 20 mg 1
• Consider alternative hypnotics (eszopiclone or zolpidem have similar evidence) 5
• Reassess in 7-10 days per FDA guidance 2

Common Pitfalls to Avoid

• Don't simply increase the dose without addressing behavioral factors—pharmacotherapy alone has limited long-term efficacy
• Don't ignore the racing thoughts—this may indicate primary anxiety requiring separate treatment
• Don't continue ineffective medication indefinitely—guidelines emphasize short-term use only 1
• Don't combine with other sedatives without careful consideration of additive CNS depression 2

The facial fatigue she describes may represent residual next-day sedation from suvorexant, which has a 12-hour half-life 4. This further supports transitioning away from this medication if it's not providing adequate benefit to justify this side effect.